TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).

How it works

Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.

What the body does with it

Metabolism	The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Excretion	TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Half-life	Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Protein binding	Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Volume of Distribution	Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
Bioavailability	IV: 100% bioavailability; not administered orally or via other routes.
Onset of Action	IV infusion: immediate onset for nitrogen balance and caloric provision; metabolic effects within minutes to hours.
Duration of Action	Duration of nutritional support is continuous during infusion. Post-infusion, metabolic effects persist for hours (amino acid oxidation, glucose regulation).

Classification & Brands

Dosing & administration

Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day, administered at a rate of 200 mL/hour, adjusted based on metabolic and fluid needs.

Dosage form	INJECTABLE
Renal impairment	In acute kidney injury or chronic kidney disease with GFR <30 mL/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Pediatric use	Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 mL/kg/day.
Geriatric use	Start at lower infusion rates (e.g., 100 mL/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).

Breastfeeding	Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
Teratogenic Risk	No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Inborn errors of amino acid metabolism","Severe hyperglycemia or hyperosmolar state","Severe electrolyte disturbances","Severe hepatic or renal failure"]

Clinical Precautions

Precautions

["Do not administer if solution is discolored or contains particulate matter","Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders","Monitor fluid and electrolyte balance, blood glucose, and acid-base status","Risk of infections related to catheter use","Rebound hypoglycemia may occur upon abrupt discontinuation"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Excretion	TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Half-life	Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Protein binding	Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Volume of Distribution	Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
Bioavailability	IV: 100% bioavailability; not administered orally or via other routes.
Onset of Action	IV infusion: immediate onset for nitrogen balance and caloric provision; metabolic effects within minutes to hours.
Duration of Action	Duration of nutritional support is continuous during infusion. Post-infusion, metabolic effects persist for hours (amino acid oxidation, glucose regulation).

Classification & Brands

Dosing & administration

Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day, administered at a rate of 200 mL/hour, adjusted based on metabolic and fluid needs.

Dosage form	INJECTABLE
Renal impairment	In acute kidney injury or chronic kidney disease with GFR <30 mL/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Pediatric use	Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 mL/kg/day.
Geriatric use	Start at lower infusion rates (e.g., 100 mL/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER).

Breastfeeding	Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
Teratogenic Risk	No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Inborn errors of amino acid metabolism","Severe hyperglycemia or hyperosmolar state","Severe electrolyte disturbances","Severe hepatic or renal failure"]